Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 384,154
  • Shares Outstanding, K 312,320
  • Annual Sales, $ 4,060 K
  • Annual Income, $ -54,050 K
  • EBIT $ -60 M
  • EBITDA $ -58 M
  • 60-Month Beta 4.54
  • Price/Sales 93.20
  • Price/Cash Flow N/A
  • Price/Book 100.11

Options Overview Details

View History
  • Implied Volatility 114.59% (-8.59%)
  • Historical Volatility 52.49%
  • IV Percentile 10%
  • IV Rank 4.97%
  • IV High 544.02% on 11/14/25
  • IV Low 92.12% on 08/19/25
  • Expected Move (DTE 8) 0.2550 (19.62%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 4,285
  • Volume Avg (30-Day) 2,901
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 68,683
  • Open Int (30-Day) 67,832
  • Expected Range 1.0450 to 1.5550

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0900 +19.27%
on 11/21/25
1.3500 -3.70%
on 11/12/25
-0.0300 (-2.26%)
since 11/11/25
3-Month
1.0500 +23.81%
on 09/12/25
1.9000 -31.58%
on 10/03/25
+0.2300 (+21.50%)
since 09/11/25
52-Week
0.5150 +152.43%
on 03/19/25
1.9000 -31.58%
on 10/03/25
+0.4300 (+49.43%)
since 12/11/24

Most Recent Stories

More News
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr....

OCGN : 1.3000 (+5.69%)
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference

MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr....

OCGN : 1.3000 (+5.69%)
Ocugen: Q3 Earnings Snapshot

Ocugen: Q3 Earnings Snapshot

OCGN : 1.3000 (+5.69%)
Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)...

OCGN : 1.3000 (+5.69%)
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

OCGN : 1.3000 (+5.69%)
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling...

OCGN : 1.3000 (+5.69%)
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

OCGN : 1.3000 (+5.69%)
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.3000 (+5.69%)
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing...

OCGN : 1.3000 (+5.69%)
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it...

OCGN : 1.3000 (+5.69%)

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 1.3167
2nd Resistance Point 1.2833
1st Resistance Point 1.2567
Last Price 1.3000
1st Support Level 1.1967
2nd Support Level 1.1633
3rd Support Level 1.1367

See More

52-Week High 1.9000
Fibonacci 61.8% 1.3709
Last Price 1.3000
Fibonacci 50% 1.2075
Fibonacci 38.2% 1.0441
52-Week Low 0.5150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar